Alignment Healthcare (NASDAQ:ALHC) CEO Sells $5,033,220.00 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO John Kao sold 298,000 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $16.89, for a total transaction of $5,033,220.00. Following the transaction, the chief executive officer owned 1,508,641 shares in the company, valued at $25,480,946.49. The trade was a 16.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alignment Healthcare Stock Performance

NASDAQ:ALHC opened at $15.73 on Friday. The firm has a market cap of $3.25 billion, a PE ratio of 174.78, a price-to-earnings-growth ratio of 2.32 and a beta of 1.26. Alignment Healthcare, Inc. has a fifty-two week low of $11.63 and a fifty-two week high of $23.87. The company has a debt-to-equity ratio of 1.56, a quick ratio of 1.58 and a current ratio of 1.58. The business has a 50 day moving average price of $19.02 and a 200-day moving average price of $19.45.

Alignment Healthcare (NASDAQ:ALHC) last released its quarterly earnings data on Thursday, April 30th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.22 billion. Alignment Healthcare had a return on equity of 11.50% and a net margin of 0.47%.The business’s quarterly revenue was up 33.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.05) earnings per share. Equities research analysts predict that Alignment Healthcare, Inc. will post 0.19 earnings per share for the current year.

Analyst Ratings Changes

ALHC has been the subject of a number of analyst reports. Robert W. Baird set a $28.00 price objective on Alignment Healthcare in a research note on Friday, January 30th. KeyCorp reissued an “overweight” rating and set a $28.00 price objective on shares of Alignment Healthcare in a research note on Thursday, January 22nd. Raymond James Financial set a $22.00 price objective on Alignment Healthcare in a research note on Thursday, May 7th. Zacks Research raised Alignment Healthcare from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 28th. Finally, TD Cowen raised their price target on Alignment Healthcare from $18.50 to $25.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $24.60.

Institutional Trading of Alignment Healthcare

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALHC. Summit Securities Group LLC purchased a new stake in Alignment Healthcare in the fourth quarter worth $26,000. Parallel Advisors LLC lifted its position in Alignment Healthcare by 87.7% during the fourth quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock valued at $33,000 after buying an additional 773 shares during the period. Larson Financial Group LLC purchased a new position in Alignment Healthcare during the third quarter valued at $33,000. First Horizon Corp purchased a new position in Alignment Healthcare during the fourth quarter valued at $39,000. Finally, GAMMA Investing LLC lifted its position in Alignment Healthcare by 83.8% during the fourth quarter. GAMMA Investing LLC now owns 2,165 shares of the company’s stock valued at $43,000 after buying an additional 987 shares during the period. Hedge funds and other institutional investors own 86.19% of the company’s stock.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.